$Verve Therapeutics(VERV.US)$However, the sixth participant treated in the 0.45 mg/kg cohort experienced a Grade 3 drug-induced transient increase in serum alanine aminotransferase (ALT) as well as a serious adverse event of Grade 3 drug-induced thrombocytopenia within the first four days after dosing. The participant did not experience any bleeding or other symptoms related to the laboratory abnormalities, and the abnormalities resolved fully within a few ...
14
举报
HUAT AH UP AH :
From the standpoint of the company, they need to clear this out before can proceed further. This is the truth.
Analysts are optimistic about Verve Therapeutics, predicting reduced losses this year, indicating a move towards profitability. Despite expected slower revenue growth, it's still anticipated to outpace the industry. However, concerns like dilutive stock issuance over the past year persist.
$Verve Therapeutics(VERV.US)$• Krishna Yeshwant, managing partner at Google Ventures and a director at Verve Therapeutics (NASDAQ:VERV), hasacquired$18M in Verve common stock. • In a transaction dated Dec 01, 2023, Yeshwant bought 1.8M shares of Verve's common stock at a price of $10 each.
$Verve Therapeutics(VERV.US)$still 400k shorts available on low volume. Could make another entry. Let the MMs lead on this one. They will decide soon enough
Verve Therapeutics might need to dilute shares significantly if it needs to cover another year's operations due to the 26% burn rate. The cash burn situation is worth monitoring for shareholders.
Verve Therapeutics股票讨论区
Read the whole PR! But reason for fall
Insider buy
• In a transaction dated Dec 01, 2023, Yeshwant bought 1.8M shares of Verve's common stock at a price of $10 each.
暂无评论